Showing 221 - 240 results of 289 for search '"glioblastoma"', query time: 0.06s Refine Results
  1. 221

    1H MR Spectroscopy in Gliomatosis: Is there a Sensitivity Issue? by M. Szewczyk-Bieda, A. K. Kanodia, G. Main, M. S. Eljamel

    Published 2011-01-01
    “…A repeat scan 6 months later showed progressive disease, and biopsy was performed that proved the diagnosis of glioblastoma. Conclusion. Normal MRS in a patient with suspicion of gliomatosis on MRI should not reassure clinicians into assuming a benign aetiology or a good prognosis in short term.…”
    Get full text
    Article
  2. 222

    Multiple Extracranial Metastases from Primary Gliosarcoma in a Patient with Two Previous Different Primary Cancers by T. Capion, J. Hauerberg, H. Broholm, A. Muhic

    Published 2019-01-01
    “…Gliosarcoma (GS) constitutes a minor fraction of primary glioblastoma (GBM), which is the most frequent malignant brain tumor in adults. …”
    Get full text
    Article
  3. 223

    Strategies for specific multimodal imaging of cancer-associated fibroblasts and applications in theranostics of cancer by Li Wen, Chengxue He, Yanhui Guo, Nina Zhou, Xiangxi Meng, Yuwen Chen, Cheng Ma, Hua Zhu, Zhi Yang, Lei Xia

    Published 2025-02-01
    “…Fibroblast activating protein (FAP) is up-regulated in cancer-associated fibroblasts (CAFs) of more than 90 % of tumor microenvironment and also highly expressed on the surface of multiple tumor cells like glioblastoma, which can be used as a specific target for tumor diagnosis and treatment. …”
    Get full text
    Article
  4. 224

    Endovascular Treatment of Vertebral Column Metastases Using Intra-Arterial Cisplatin: Pilot Experience by Bohdan W. Chopko

    Published 2014-01-01
    “…Intra-arterial chemotherapy is an uncommonly used but established treatment for head and neck cancers, retinoblastoma, and glioblastoma. The author reports extension of the IAC concept to vertebral metastatic tumors. …”
    Get full text
    Article
  5. 225

    Measuring Brain Tumor Growth: Combined Bioluminescence Imaging–Magnetic Resonance Imaging Strategy by Sarah C. Jost, Lynne Collins, Sarah Travers, David Piwnica-Worms, Joel R. Garbow

    Published 2009-09-01
    “…Herein we describe combining BLI and MRI studies to characterize tumor growth in a mouse model of glioblastoma. The results led us to suggest a cost-effective, multimodality strategy for selecting cohorts of animals with similar tumor growth patterns that improves the accuracy of longitudinal in vivo measurements of tumor growth and treatment response in preclinical therapeutic studies.…”
    Get full text
    Article
  6. 226

    PTEN Gene: A Model for Genetic Diseases in Dermatology by Corrado Romano, Carmelo Schepis

    Published 2012-01-01
    “…Somatic mutations of PTEN have been observed in glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the first tissues where the involvement has been proven. …”
    Get full text
    Article
  7. 227

    Botulinum Therapy for Pain Caused by Spasticity in Advanced Stages of Brain Tumor in Adolescents: A Case Report by Tomoo Mano, Toshiharu Murakami, Haruki Mori, Takashi Masuda

    Published 2025-01-01
    “…Case presentation: A 15-year-old female patient experienced dizziness, developed muscle weakness in her upper extremities, and was diagnosed with diffuse glioblastoma of the pons. The tumor responded partially to radiation therapy. …”
    Get full text
    Article
  8. 228

    Promising Neuroprotective Effects of Dracocephalum Species: Mechanistic Perspectives by Marjan Talebi, Alireza Ghassempour, Afsoon Feizi, Seyed Abdulmajid Ayatollahi, Mehrdad Faizi

    Published 2024-12-01
    “…The role of the genus Dracocephalum was investigated in relation to various neurological conditions such as Alzheimer's disease, insomnia, Parkinson's disease, vascular dementia, cerebral ischemia, pain, depression, and glioblastoma. These findings suggest that Dracocephalum spp. and their phytochemicals have neuroprotective effects by targeting the regulation of various pathways. …”
    Get full text
    Article
  9. 229

    Micro-PET Imaging of αβ-Integrin Expression with F-Labeled Dimeric RGD Peptide by Xiaoyuan Chen, Michel Tohme, Ryan Park, Yingping Hou, James R. Bading, Peter S. Conti

    Published 2004-04-01
    “…The resulting [ 18 F]FB-E[c(RGDyK)] 2 , with high specific activity (200–250 GBq/μmol at the end of synthesis), was administered to subcutaneous U87MG glioblastoma xenograft models for micro-PET and autoradiographic imaging as well as direct tissue sampling to assess tumor targeting efficacy and in vivo kinetics of this PET tracer. …”
    Get full text
    Article
  10. 230

    Complementary Use of Bioluminescence Imaging and Contrast-Enhanced Micro—Computed Tomography in an Orthotopic Brain Tumor Model by Sanaz Yahyanejad, Patrick V. Granton, Natasja G. Lieuwes, Lesley Gilmour, Ludwig Dubois, Jan Theys, Anthony J. Chalmers, Frank Verhaegen, Marc Vooijs

    Published 2014-01-01
    “…A widely used orthotopic glioblastoma multiforme (GBM) tumor model was applied in nude mice, and tumor growth was evaluated by BLI and contrast-enhanced microCT imaging. …”
    Get full text
    Article
  11. 231

    Inhibition of GPR68 induces ferroptosis and radiosensitivity in diverse cancer cell types by Leif R. Neitzel, Daniela T. Fuller, Jessica Cornell, Samantha Rea, Carolina de Aguiar Ferreira, Charles H. Williams, Charles C. Hong

    Published 2025-02-01
    “…Previously, using ogremorphin (OGM), a small molecule inhibitor of GPR68, an extracellular proton sensing receptor, we demonstrated that GPR68 is a key pro-survival pathway in glioblastoma cells. Here, we demonstrate that GPR68 inhibition also induces ferroptosis in lung cell carcinoma (A549) and pancreatic ductal adenocarcinoma (Panc02) cells. …”
    Get full text
    Article
  12. 232

    Impact of Temozolomide on Immune Response during Malignant Glioma Chemotherapy by Sadhak Sengupta, Jaclyn Marrinan, Caroline Frishman, Prakash Sampath

    Published 2012-01-01
    “…Malignant glioma, or glioblastoma, is the most common and lethal form of brain tumor with a median survival time of 15 months. …”
    Get full text
    Article
  13. 233

    The Pivotal Immunomodulatory and Anti-Inflammatory Effect of Histone-Lysine N-Methyltransferase in the Glioma Microenvironment: Its Biomarker and Therapy Potentials by Seidu A. Richard, Kuugbee D. Eugene

    Published 2021-01-01
    “…EZH2 was more secreted in glioblastoma multiforme than in low-grade gliomas as well as extremely secreted in U251 and U87 human glioma cells. …”
    Get full text
    Article
  14. 234

    Integrative analysis of SEPN1 in glioma: Prognostic roles, functional implications, and potential therapeutic interventions. by Zisong Wang, Danwen Wang, Xuanyu Wang, Yihang Xu, Yunhe Yuan, Yuxin Chen, Zhiqiang Li, Xiaoping Liu

    Published 2025-01-01
    “…Suppressing SEPN1 in glioblastoma cells inhibited proliferation and induced G2/M arrest and apoptosis. …”
    Get full text
    Article
  15. 235

    Primary Gliosarcoma of the Cerebellum in a Young Pregnant Woman: Management Challenges and Immunohistochemical Features by Marco Meloni, Salvatore Serra, Giulia Bellisano, Nikolaos Syrmos, Sanjeeva Jeyaretna, Mario Ganau

    Published 2019-01-01
    “…GS should be considered in the differential diagnosis of posterior cranial fossa tumors with radiological features of meningioma or glioblastoma, even in young patients. To this regard, sarcomas, solitary fibrous tumors, and even metastases should be considered, especially in light of the tendency of GS to give rise to extracranial localizations. …”
    Get full text
    Article
  16. 236

    TERTp Mutation and its Prognostic Value in Glioma Patients Under the 2021 WHO Classification: A Real‐World Study by Hao Xing, Delin Liu, Junlin Li, Yulu Ge, Xiaopeng Guo, Wenlin Chen, Dachun Zhao, Yixin Shi, Yilin Li, Yaning Wang, Yuekun Wang, Yu Xia, Jiaming Wu, Tingyu Liang, Hai Wang, Qianshu Liu, Shanmu Jin, Tian Qu, Siying Guo, Huanzhang Li, Tianrui Yang, Kun Zhang, Yu Wang, Wenbin Ma

    Published 2025-01-01
    “…Moreover, TERTp mutation tended to co‐occur with EGFR, KRAS, and MET in glioblastoma. In the IDH‐mutant subgroup, it tended to co‐occur with CIC and FUBP1 alterations, while being mutually exclusive with ATRX and TP53 alterations. …”
    Get full text
    Article
  17. 237

    Update on the Progress of Musashi-2 in Malignant Tumors by Yiting Niu, Tao Zhou, Yanjun Li

    Published 2025-01-01
    “…As a significant member of the MSI family, MSI2 is closely associated with multiple malignant tumors, including hematological disorders, common abdominal tumors, and other tumor types (e.g., glioblastoma, breast cancer). MSI2 is highly expressed in the majority of tumors and is related to a poor disease prognosis. …”
    Get full text
    Article
  18. 238

    Cinnamaldehyde impacts key cellular signaling pathways for induction of programmed cell death in high-grade and low-grade human glioma cells by Yoo Na Kim, Ketki Patil, S. Balakrishna Pai

    Published 2025-01-01
    “…Gliomas comprise high-grade gliomas like glioblastoma multiforme (GBMs), many of which have mutation in the tumor suppressor p53 gene and low-grade gliomas (LGGs). …”
    Get full text
    Article
  19. 239

    Innovative ultrasound assisted synthesis of sponge like cerium dioxide nanostructure using Rosa Damascena extract and its efficient performance for cancer therapy by Mahnaz Amiri, Sahar Zinatloo-Ajabshir, Meysam Ahmadi-Zeidabadi, Fariborz Sharifianjazi

    Published 2025-01-01
    “…The cytotoxicity effect of CeO2 NPs on glioblastoma and neuroblastoma cell lines (T98, SHSY5Y) was studied using the MTT test; cerium oxide nanoparticles exhibited cytotoxicity effects on T98 and SHSY5Y cell lines, compared to the control. …”
    Get full text
    Article
  20. 240

    Predicting survival in malignant glioma using artificial intelligence by Wireko Andrew Awuah, Adam Ben-Jaafar, Subham Roy, Princess Afia Nkrumah-Boateng, Joecelyn Kirani Tan, Toufik Abdul-Rahman, Oday Atallah

    Published 2025-01-01
    “…Abstract Malignant gliomas, including glioblastoma, are amongst the most aggressive primary brain tumours, characterised by rapid progression and a poor prognosis. …”
    Get full text
    Article